Neuroendocrinology: Improved progression-free survival with everolimus plus octreotide in carcinoid syndrome

  • Linda Koch
  • Published 2011 in Nature Reviews Endocrinology


Everolimus plus octreotide improves progression-free survival in patients with advanced neuroendocrine tumors (NETs) associated with carcinoid syndrome compared with placebo plus octreotide. The diagnosed incidence of advanced NETs has risen more than fivefold over the past three decades. These tumors, which are not curable, can arise from neuroendocrine… (More)
DOI: 10.1038/nrendo.2011.230


  • Presentations referencing similar topics